Your Security Tools Are Not Proof Someone Is Watching Your Biotech Network
There is a dangerous assumption inside many biotech companies:
If the security tools are running, the network is being monitored and it must be secure.
That is not necessarily true.
Your firewall can be running.
Your endpoints can have EDR.
Your SIEM can collect millions of events.
Your Microsoft environment can generate security alerts.
Your security dashboard can be completely green at 5:00 p.m.
None of that answers the question that matters when something suspicious happens at 2:17 a.m.:
Who is actually watching, and what happens next?
That distinction matters enormously in biotech because a security failure does not simply threaten computers. It can threaten intellectual property, research information, proprietary processes, clinical information, manufacturing knowledge and other assets that may represent years of investment before they ever produce meaningful revenue.
For a biotech company, cybersecurity is ultimately connected to enterprise value.
Monitoring Is Not the Same as Collecting Alerts
Security leaders should challenge one of the industry’s most comfortable assumptions: deploying detection technology creates security coverage.
It doesn’t.
NIST’s Cybersecurity Framework 2.0 treats detecting cybersecurity activity and responding to incidents as distinct cybersecurity functions. Detection should enable timely discovery and analysis of potentially adverse events; response addresses what the organization does after an incident has been detected.
That separation is important.
- An alert can exist without being investigated.
- A suspicious authentication can be recorded without anyone determining whether the account is compromised.
- An endpoint can generate an event without anyone examining what happened before or after it.
CISA similarly emphasizes that logging and monitoring allow organizations to identify suspicious activity and respond more quickly. The objective is not simply possessing the logs. It is turning visibility into action.
That creates an uncomfortable question for biotech security leadership:
Can you prove someone is monitoring your environment, or can you only prove your tools are generating data?
Those are very different things.
Take the 2:17 A.M. Test
Imagine an employee account authenticates from an unusual location at 2:17 a.m.
Minutes later, another security system notices suspicious access to a repository containing proprietary research information.
Your technology generates alerts.
Now what?
Don’t answer with the name of your SIEM.
Answer these questions instead:
- Who receives the first alert?
- How quickly must that person acknowledge it?
- Who investigates whether the two events are related?
- Does that individual have enough security experience to distinguish an actual compromise from normal activity?
- Who checks what the account accessed?
- Who determines whether credentials should be disabled?
- Who contacts the internal security leader?
- What is the escalation threshold?
- What happens if your primary security employee is asleep, unavailable, sick or on vacation?
- And by 8:00 the next morning, can your CISO reconstruct exactly what happened?
That is threat monitoring.
The rest is instrumentation.
Why This Problem Becomes More Serious in Biotech
A traditional business may primarily think about cyber risk in terms of downtime, fraud or stolen customer information.
Biotech leadership must think more broadly.
Some of the company’s most valuable assets may exist as information long before they generate commercial revenue.
Consider the implications of losing proprietary research data, manufacturing information, formulations, experimental information or other trade secrets.
The importance of intellectual property to biotech valuation is not theoretical.
In the JHL Biotech case, the U.S. Department of Justice prosecuted executives over a conspiracy involving Genentech trade secrets related to biopharmaceutical products. DOJ reported that JHL had reached a valuation of approximately $916 million before its value later collapsed amid the underlying trade-secret dispute. The case involved alleged trade-secret theft rather than a conventional network intrusion, but it illustrates something security leaders should not ignore: biotechnology enterprise value can be deeply connected to information assets competitors cannot recreate easily.
That makes the monitoring question much bigger than IT.
- What would leadership need to explain if sensitive research information were accessed for several hours before anyone investigated?
- What would the board ask?
- What would investors want to know?
- What would potential partners question?
- And how comfortable would leadership be answering, “The security system generated an alert, but nobody investigated it until morning”?
Your Internal IT Team May Not Be the Problem
This is where security conversations often become unfair.
Leadership concludes that the internal IT or security team needs to “watch more closely.”
That misses the operating problem.
A small biotech may have highly capable IT people who are already responsible for identity, endpoints, cloud environments, vendors, employee requests, vulnerability remediation, compliance requirements, projects and infrastructure.
Then leadership quietly expects those same people to provide continuous threat investigation.
That isn’t strategy.
That is dependency on individual availability.
One person cannot realistically provide continuous coverage every hour of every day while also performing a normal operational role.
The right question isn’t:
“Why isn’t our internal team doing more?”
It is:
“Have we designed a security operating model that gives our team the coverage they need?”
What Real Monitoring Should Be Able to Prove
A security director should be able to demonstrate five things without preparing for three weeks.
Visibility
Are the important systems producing usable security telemetry?
Ownership
Is somebody clearly responsible when a critical event appears?
Investigation
Does a qualified analyst determine what happened rather than simply forwarding the alert?
Escalation
Are severity thresholds, communication paths and response expectations documented?
Evidence
Can leadership see when the alert occurred, when investigation began, what was discovered and what actions were taken?
If you cannot demonstrate those capabilities overnight, during weekends and during employee absences, you do not have continuous monitoring.
You have partial monitoring.
That may be acceptable if leadership knowingly accepts the risk.
The dangerous situation is believing you have 24/7 coverage when you don’t.
Managed Security Is an Operating Model, Not an Admission of Failure
This is where managed security services deserve a different conversation.
The strategic value isn’t “outsourcing cybersecurity.”
It is extending the operating capacity of the security organization.
A strong managed security model can provide dedicated analysts, overnight coverage, defined escalation processes, documented investigation procedures and contractual service levels around acknowledgment or escalation.
Internal leadership still owns security strategy.
The external team provides additional operational capacity.
That is especially important for biotech companies that cannot justify building a fully staffed 24/7 security operation internally but cannot tolerate a twelve-hour gap between detection and investigation either.
Stop Asking Whether Your Tools Are Working
Ask whether your security operating model works when your people aren’t available.
Run the 2:17 a.m. scenario.
Request the evidence.
Measure the response chain.
Ask who investigates.
Ask how quickly.
Ask what happens next.
If the answers depend heavily on who happens to notice an alert, your biggest security problem may not be technology.
It may be coverage.
And if leadership cannot confidently prove that critical threats are being investigated around the clock, a security assessment should not begin with a shopping list of new tools.
It should begin by testing the monitoring and response model you already have.
Because the question that ultimately matters is not whether your biotech owns enough cybersecurity technology.
It is whether the operating model protecting your intellectual property is strong enough to protect the value you are trying to build.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
